The FDA has endorsed Pfizer’s respiratory ... While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how ...
Medpage Today on MSN1d
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
On Tuesday, the FDA approved Pfizer Inc’s (NYSE ... with 65% opting for GSK's Arexvy. However, this September, the weekly average fell to 157,000. Price Action: PFE stock is down 0.36% at ...
The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...
The FDA has approved Pfizer’s respiratory syncytial ... for severe RSV should receive a single dose of the RSV vaccine (Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]).
Sales of all three FDA-approved vaccines in the 2024-25 season will be scrutinised to gauge the impact of that new advice. Last year, Arexvy came out on top in the market tussle with sales of $1.6 ...
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
GSK is also conducting clinical studies on Arexvy for expanded use in adults aged 18-49 years. Moderna MRNA secured FDA approval for its mRNA-based RSV vaccine, mResvia, this May to prevent RSV ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback